Teva surpassed all targets tied to approximately $7.5 billion of sustainability-linked bonds issued in 2021 and 2023, linking bond pricing to metrics on climate action, health equity and access to medicines. This achievement underscores the company’s strategy of integrating financial performance with sustainability commitments to potentially lower its cost of capital.

The company cut Scope 1 and 2 greenhouse gas emissions by 39% since 2019 and Scope 3 emissions by 32% since 2020, each exceeding 25% reduction goals. Teva now sources 60% of its electricity from renewables and has secured 100% renewable electricity through long-term power purchase agreements covering key sites.

Through eight global access programs, Teva reached nearly 8 million people with product donations and supported 399,000 individuals via health system strengthening. Its generics portfolio generated $36.4 billion in savings for healthcare systems across 21 countries, while over 99% of employees completed compliance and ethics training and the company ranked in the top 10% of its sector on major sustainability benchmarks.